- Home
- BSX vs PRME Comparison
BSX vs PRME Comparison
Compare BSX & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSX
- PRME
- Stock Information
- Founded
- BSX 1979
- PRME 2019
- Country
- BSX United States
- PRME United States
- Employees
- BSX N/A
- PRME N/A
- Industry
- BSX Medical/Dental Instruments
- PRME Medicinal Chemicals and Botanical Products
- Sector
- BSX Health Care
- PRME Health Care
- Exchange
- BSX Nasdaq
- PRME Nasdaq
- Market Cap
- BSX 157.6B
- PRME 693.5M
- IPO Year
- BSX 1992
- PRME 2022
- Fundamental
- Price
- BSX $101.13
- PRME $5.43
- Analyst Decision
- BSX Strong Buy
- PRME Buy
- Analyst Count
- BSX 19
- PRME 6
- Target Price
- BSX $124.53
- PRME $8.88
- AVG Volume (30 Days)
- BSX 10.0M
- PRME 4.1M
- Earning Date
- BSX 10-22-2025
- PRME 11-11-2025
- Dividend Yield
- BSX N/A
- PRME N/A
- EPS Growth
- BSX 54.68
- PRME N/A
- EPS
- BSX 1.87
- PRME N/A
- Revenue
- BSX $19,349,000,000.00
- PRME $4,961,000.00
- Revenue This Year
- BSX $19.87
- PRME $179.58
- Revenue Next Year
- BSX $11.06
- PRME N/A
- P/E Ratio
- BSX $54.07
- PRME N/A
- Revenue Growth
- BSX 21.61
- PRME 739.42
- 52 Week Low
- BSX $80.64
- PRME $1.11
- 52 Week High
- BSX $109.50
- PRME $6.94
- Technical
- Relative Strength Index (RSI)
- BSX 55.26
- PRME 49.35
- Support Level
- BSX $99.29
- PRME $4.93
- Resistance Level
- BSX $105.49
- PRME $6.30
- Average True Range (ATR)
- BSX 1.95
- PRME 0.62
- MACD
- BSX 0.89
- PRME -0.16
- Stochastic Oscillator
- BSX 60.22
- PRME 23.38
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.